Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

November 26, 2019

Study Completion Date

February 28, 2020

Conditions
SepsisSeptic ShockMetabolic Disturbance
Interventions
DRUG

vitamin C, vitamin B1, hydrocortisone

Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.

DRUG

Normal saline

Normal saline (0.9% NaCl solution) volume to match all components

Trial Locations (13)

11030

North Shore University Hospital, Manhasset

11040

Long Island Jewish Hospital, New York

15213

University Of Pittsburgh Medical Center, Pittsburgh

48073

Beaumont Hospital, Royal Oak

48201

Detroit Receiving Hospital, Detroit

Harper University Hospital, Detroit

48202

Henry Ford Hospital, Detroit

48235

Sinai Grace Hospital, Detroit

77030

The University of Texas Health Science Center, Houston

85054

Mayo Clinic - Arizona, Phoenix

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

02138

Mount Auburn Hospital, Cambridge

All Listed Sponsors
collaborator

Open Philanthropy

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03389555 - Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial | Biotech Hunter | Biotech Hunter